Browsing category:

Monoclonal Antibodies / mAb


Exciting news was presented at ENDO 2015 regarding the use of Denosumab for osteoporosis in post-menopausal women who are at high risk for bone fractures. Results from a comprehensive trial coined Freedom showed the use of Denosumab successfully increased bone mineral density (BMD) at cortical bone sites, particularly the 1/3 radius skeletal site which does[…]

Read More

Known as the blockbuster brand name anticancer therapy Avastin, Bevacizumab recently captured a positive opinion from the EU for its success in treating cervical cancer. On March 2, 2015 Roche Pharmaceuticals announced that the European Union’s (EU) Committee for Medicinal Products for Human Use expressed a positive opinion of Bevacizumab when used alongside standard chemotherapy[…]

Read More

Known as the brand name Campath, which is marketed by Genzyme, Alemtuzumab is a proven therapy for leukemias, lymphomas and recently, multiple sclerosis. As a monoclonal antibody Alemtuzumab effectively binds to the CD52 protein which occurs on cancerous B and T cell lymphocytes. After attaching to the protein on the cells Alemtuzumab elicits other immune[…]

Read More

Alemtuzumab, also known as the brand name MS drug Lemtrada, has recently gained a long awaited FDA approval. Genzyme spent over a decade developing this long-acting agent designed to effectively treat patients with relapsing Multiple Sclerosis. The unique method of dispensing Alemtuzumab is a significant plus for patients who do not tolerate current medication regimens[…]

Read More

The EU approved the formidable drug Tocilizumab, also known as the brand name RoACTEMRA, which is marketed by Roche Pharmaceuticals, at the end of April 2014. As the only FDA approved medication for treating systemic JIA and polyarticular JIA in children, Tocilizumab is well regarded in the United States. Tocilizumab is approved by both the[…]

Read More

The recent approval of Ofatumumab by the FDA is exciting news for the medical and pharmaceutical world. As a monoclonal antibody used to treat chronic lymphocytic leukemia, Ofatumumab garnished a Supplemental Biologic License Application in late April 2014. Known as the brand name drug Arzerra, which is marketed by both GlaxoSmithKline and Genmab this unique[…]

Read More

Exciting news was revealed from Genzyme at the beginning of February 2014, with the announcement that their formidable multiple sclerosis drug, Alemtuzumab, had been approved for use in Mexico. Known as the brand name Lemtrada, Alemtuzumab is specifically effectual for patients with relapsing remitting multiple sclerosis, also coined RRMS. This extremely common and debilitating form[…]

Read More

At the end of January 2014 the powerful drug Eculizumab received orphan drug status from the FDA as a preventative treatment of delayed graft function (DGF) for renal transplant patients. Eculizumab is already approved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Paroxysmal nocturnal hemoglobinuria or PNH is a rare form of anemia[…]

Read More

Health Canada has approved Alemtuzumab. Alemtuzumab will be marketed by Genzyme as Lemtrada for the treatment of relapsing remitting multiple sclerosis (RRMS), with active disease, who have not shown an adequate response to interferon beta or other disease-modifying therapies. Alemtuzumab is a monoclonal antibody which targets the CD52 protein. The drug was used for several[…]

Read More